Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dabrafenib versus chemotherapy for relapsed or refractory pediatric BRAF-V600E-positive Langerhans cell histiocytosis
ChiCTR2000039420Phase 4Recruiting
- Sponsor
- Beijing Children's Hospital
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dabrafenib + trametinib in Langerhans cell histiocytosis (LCH) (2 arms), sponsored by Beijing Children's Hospital. Primary endpoints: Progression-free survival, Overall response rate and 2 more. Started Nov 2020; status: recruiting.
02
Drugs
dabrafenib + trametinib
03
Conditions
Langerhans cell histiocytosis (LCH)
Beyond the preview
Go deeper on ChiCTR2000039420.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000039420.